Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary Medullary thyroid carcinoma

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Hedayati, Mehdi ^a   Yeganeh, Marjan Zarif ^a   Eslami, Sara Sheikhol ^b   Barez, Shekoofe Rezghi ^b   Rad, Laleh Hoghooghi ^a   Azizi, Fereidoun ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CYSTEINE; GENOMIC DNA; GLYCINE; SERINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CELL TRANSFORMATION; CODON; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; DNA SEQUENCE; ETHNIC GROUP; EXON; FEMALE; GENE IDENTIFICATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; INTRON; IRANIAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTO ONCOGENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RET GENE; THYROID MEDULLARY CARCINOMA;

EID: 84880625774     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/264248     Document Type: Article

References (36)

1. M. N. Nikiforova and Y. E. Nikiforov, "Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis", Expert Review of Molecular Diagnostics, vol. 8, no. 1, pp. 83-95, 2008.
2. S. Dvoraka, E. Vaclavíkova, V. Sykorova et al., "New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma", Thyroid, vol. 16, no. 3, pp. 311-316, 2006.
3. M. M. Moura, B. M. Cavaco, A. E. Pinto et al., "Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas", British Journal of Cancer, vol. 100, no. 11, pp. 1777-1783, 2009.
4. D. J. Marsh, D. L. Learoyd, and B. G. Robinson, "Medullary thyroid carcinoma: recent advances and management update", Thyroid, vol. 5, no. 5, pp. 407-424, 1995.
5. R. Elisei, B. Cosci, C. Romei et al., "Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study", Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 3, pp. 682-687, 2008. (Pubitemid 351398539)
6. R. S. Sippel, M. Kunnimalaiyaan, and H. Chen, "Current management of medullary thyroid cancer", Oncologist, vol. 13, no. 5, pp. 539-547, 2008. (Pubitemid 351872871)
7. R. V. Thakker, "Multiple endocrine neoplasia-syndromes of the twentieth century", Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 8, pp. 2617-2620, 1998. (Pubitemid 28493749)
8. H. Donis-Keller, S. Dou, D. Chi et al., "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC", Human Molecular Genetics, vol. 2, no. 7, pp. 851-856, 1993. (Pubitemid 23216611)
9. C. G. P. Mathew, K. S. Chin, D. F. Easton et al., "A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10", Nature, vol. 328, no. 6130, pp. 527-528, 1987. (Pubitemid 17098353)
10. S. Shirahama, K. Ogura, H. Takami et al., "Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma", Journal of Human Genetics, vol. 43, no. 2, pp. 101-106, 1998. (Pubitemid 128508963)
11. S. Manié, M. Santoro, A. Fusco, and M. Billaud, "The RET receptor: function in development and dysfunction in congenital malformation", Trends in Genetics, vol. 17, no. 10, pp. 580-589, 2001. (Pubitemid 32918300)
12. M. P. Cosma, M. Cardone, F. Carlomagno, and V. Colantuoni, "Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism", Molecular and Cellular Biology, vol. 18, no. 6, pp. 3321-3329, 1998. (Pubitemid 28240504)
13. S. Bethanis, G. Koutsodontis, T. Palouka et al., "A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A", Hormones, vol. 6, no. 2, pp. 152-156, 2007.
14. J. Grimm, M. Sachs, S. Britsch et al., "Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation", Journal of Cell Biology, vol. 154, no. 2, pp. 345-354, 2001. (Pubitemid 34286145)
15. C. J. M. Lips, J. W. M. Höppener, and J. H. H. Thijssen, "Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement", Annals of Clinical Biochemistry, vol. 38, part 3, no. 3, pp. 168-179, 2001. (Pubitemid 32429998)
16. R. Elisei, C. Romei, B. Cosci, L. Agate, V. Bottici, E. Molinaro et al., "RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center", Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 12, pp. 4725-4729, 2007. (Pubitemid 350223450)
17. N. Wohllk, G. J. Cote, M. M. J. Bugalho et al., "Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma", Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 10, pp. 3740-3745, 1996. (Pubitemid 26339948)
18. M. Lallier, D. St-Vil, M. Giroux et al., "Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome", Journal of Pediatric Surgery, vol. 33, no. 6, pp. 846-848, 1998. (Pubitemid 28280809)
19. C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R. F. Gagel et al., "The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis", Journal of the American Medical Association, vol. 276, no. 19, pp. 1575-1579, 1996. (Pubitemid 26384740)
20. S. Chappuis-Flament, A. Pasini, G. de Vita et al., "Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines", Oncogene, vol. 17, no. 22, pp. 2851-2861, 1998, Laboratoire de Génétique, CNRS UMR 5641, Domaine Rockefeller, Lyon, France. (Pubitemid 29010055)
21. M. Santoro, F. Carlomagno, A. Romano et al., "Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B", Science, vol. 267, no. 5196, pp. 381-383, 1995.
22. C. Eng, P. A. Crossey, L. M. Mulligan et al., "Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas", Journal of Medical Genetics, vol. 32, no. 12, pp. 934-937, 1995.
23. M. Hedayati, I. Nabipour, N. Rezaei-Ghaleh, and F. Azizi, "Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases", Medical Journal of Malaysia, vol. 61, no. 5, pp. 564-569, 2006. (Pubitemid 46569503)
24. M. Hedayati, M. Zarif Yeganeh, M. Daneshpour, M. Ahmadi, and F. Azizi, "Frequent germline mutation in RET protooncogene exons 10 and 11 in hereditary MTC of Iranian patients", Kowsar Medical Journal, vol. 15, no. 1, pp. 17-21, 2010.
25. Y. Zhou, Y. Zhao, B. Cui et al., "RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland chinese families with MEN2A and MEN2B", Clinical Endocrinology, vol. 67, no. 4, pp. 570-576, 2007. (Pubitemid 47416316)
26. L. M. Mulligan, C. Eng, C. S. Healey et al., "Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC", Nature Genetics, vol. 6, no. 1, pp. 70-74, 1994. (Pubitemid 24191916)
27. A. Machens, P. Niccoli-Sire, J. Hoegel et al., "Early malignant progression of hereditary medullary thyroid cancer", The New England Journal of Medicine, vol. 349, no. 16, pp. 1517-1525, 2003. (Pubitemid 37255037)
28. K. Frank-Raue, A. Machens, C. Scheuba, B. Niederle, H. Dralle, and F. Raue, "Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791", Clinical Endocrinology, vol. 69, no. 2, pp. 259-263, 2008. (Pubitemid 352009032)
29. I. Schuffenecker, M. Virally-Monod, R. Brohet et al., "Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe d'etude des tumeurs a calcitonine", Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 2, pp. 487-491, 1998. (Pubitemid 28496527)
30. E. Saggiorato, I. Rapa, F. Garino et al., "Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia", Journal of Molecular Diagnostics, vol. 9, no. 2, pp. 214-219, 2007. (Pubitemid 47305088)
31. E. Alvandi, S. M. Akrami, M. Chiani et al., "Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population", Thyroid, vol. 2, no. 4, pp. 373-382, 2011.
32. R. M. Fernández, E. Navarro, G. Antiãolo, M. Ruiz-Ferrer, and S. Borrego, "Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients", International Journal of Molecular Medicine, vol. 17, no. 4, pp. 575-581, 2006.
33. I. Berard, J. L. Kraimps, F. Savagner et al., "Germlinesequence variants S836S and L769L in the RE arranged during transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the french population", Clinical Genetics, vol. 65, no. 2, pp. 150-152, 2004. (Pubitemid 38220117)
34. G. Pinna, G. Orgiana, A. Riola et al., "RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype", Thyroid, vol. 17, no. 2, pp. 101-104, 2007. (Pubitemid 46365563)
35. T Nasser, F. Qari, A Karawgh, and J. Al Aama, "RET codon 618 mutations is the most frequent phenotype in Saudi families with multiple endocrine neoplasia type 2A", in Proceedings of the European Congress of Endocrinology, vol. 22, p. 380, European Society of Endocrinology, Prague, Czech Republic, April 2010.
36. M. Robledo, L. Gil, M. Pollán et al., "Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A", Cancer Research, vol. 63, no. 8, pp. 1814-1817, 2003. (Pubitemid 36460842)